Vyome Holdings, Inc. (HIND) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Vyome Holdings, Inc. (HIND) has a cash flow conversion efficiency ratio of 1.108x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($4.34 Million) by net assets ($3.92 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Vyome Holdings, Inc. defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Vyome Holdings, Inc. - Cash Flow Conversion Efficiency Trend (2005–2024)
This chart illustrates how Vyome Holdings, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Vyome Holdings, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vyome Holdings, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Varopakorn Public Company Limited
BK:VARO
|
0.381x |
|
Schroder Oriental Income Fund
LSE:SOI
|
0.126x |
|
BBGI SICAV SA
LSE:BBGI
|
-0.008x |
|
Zinitix Co.Ltd
KQ:303030
|
-0.124x |
|
Regenbogen AG
F:RGB
|
0.022x |
|
BIOEXTRAX AB
F:85X0
|
N/A |
|
AIM Commercial Growth Freehold And Leasehold Real Estate Investment Trust
BK:AIMCG
|
0.005x |
|
Finlay Minerals Ltd
V:FYL
|
0.037x |
Annual Cash Flow Conversion Efficiency for Vyome Holdings, Inc. (2005–2024)
The table below shows the annual cash flow conversion efficiency of Vyome Holdings, Inc. from 2005 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Vyome Holdings, Inc..
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-253.00K | $-4.43 Million | 17.498x | +787.44% |
| 2023-12-31 | $6.66 Million | $-16.96 Million | -2.545x | +57.45% |
| 2022-12-31 | $3.66 Million | $-21.90 Million | -5.983x | -1625.07% |
| 2021-12-31 | $44.33 Million | $-15.38 Million | -0.347x | +41.23% |
| 2020-12-31 | $14.49 Million | $-8.55 Million | -0.590x | -0.19% |
| 2019-12-31 | $24.11 Million | $-14.20 Million | -0.589x | +32.16% |
| 2018-12-31 | $31.66 Million | $-27.49 Million | -0.868x | -169.66% |
| 2017-12-31 | $76.37 Million | $-24.59 Million | -0.322x | +95.42% |
| 2016-12-31 | $2.94 Million | $-20.66 Million | -7.028x | -14.19% |
| 2015-12-31 | $3.67 Million | $-22.61 Million | -6.155x | -111.59% |
| 2014-12-31 | $6.66 Million | $-19.38 Million | -2.909x | -131.72% |
| 2013-12-31 | $14.68 Million | $-18.43 Million | -1.255x | +33.69% |
| 2012-12-31 | $11.88 Million | $-22.48 Million | -1.893x | -90.30% |
| 2011-12-31 | $20.04 Million | $-19.94 Million | -0.995x | -116.26% |
| 2010-12-31 | $29.71 Million | $-13.66 Million | -0.460x | +89.59% |
| 2009-12-31 | $5.58 Million | $-24.66 Million | -4.418x | -49.66% |
| 2008-12-31 | $11.41 Million | $-33.67 Million | -2.952x | -472.02% |
| 2007-12-31 | $45.28 Million | $-23.37 Million | -0.516x | +9.13% |
| 2006-12-31 | $28.57 Million | $-16.23 Million | -0.568x | +89.09% |
| 2005-12-31 | $1.97 Million | $-10.28 Million | -5.205x | -- |
About Vyome Holdings, Inc.
Vyome Holdings Inc., a clinical-stage healthcare company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States and global markets. The company was founded in 2017 and is based in Cambridge, Massachusetts.